CN113242858A - 一类蛋白受体激酶抑制剂的制备和应用 - Google Patents

一类蛋白受体激酶抑制剂的制备和应用 Download PDF

Info

Publication number
CN113242858A
CN113242858A CN201980067895.1A CN201980067895A CN113242858A CN 113242858 A CN113242858 A CN 113242858A CN 201980067895 A CN201980067895 A CN 201980067895A CN 113242858 A CN113242858 A CN 113242858A
Authority
CN
China
Prior art keywords
substituted
unsubstituted
ring
compound
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980067895.1A
Other languages
English (en)
Inventor
江磊
冯志勇
路小丽
尚珂
寿建勇
吴淡宜
徐圆
许灵灵
张淑芸
张宇星
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Ennovabio Pharmaceuticals Co Ltd
Original Assignee
Shanghai Ennovabio Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Ennovabio Pharmaceuticals Co Ltd filed Critical Shanghai Ennovabio Pharmaceuticals Co Ltd
Publication of CN113242858A publication Critical patent/CN113242858A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明提供了一种蛋白受体激酶抑制剂的制备方法。具体地，本发明公开了一种式I所示的化合物或其立体异构体或外消旋体或其药学上可接受的盐，其中，各基团的定义如说明书中所述。本发明还公开了上述化合物作为TRK激酶抑制剂的用途。

Description

PCT国内申请，说明书已公开。

Claims (10)

  1. PCT国内申请，权利要求书已公开。
CN201980067895.1A 2018-10-15 2019-10-15 一类蛋白受体激酶抑制剂的制备和应用 Pending CN113242858A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018112014893 2018-10-15
CN201811201489.3A CN111039947A (zh) 2018-10-15 2018-10-15 一类蛋白受体激酶抑制剂的制备和应用
PCT/CN2019/111334 WO2020078360A1 (zh) 2018-10-15 2019-10-15 一类蛋白受体激酶抑制剂的制备和应用

Publications (1)

Publication Number Publication Date
CN113242858A true CN113242858A (zh) 2021-08-10

Family

ID=70230441

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201811201489.3A Pending CN111039947A (zh) 2018-10-15 2018-10-15 一类蛋白受体激酶抑制剂的制备和应用
CN201980067895.1A Pending CN113242858A (zh) 2018-10-15 2019-10-15 一类蛋白受体激酶抑制剂的制备和应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201811201489.3A Pending CN111039947A (zh) 2018-10-15 2018-10-15 一类蛋白受体激酶抑制剂的制备和应用

Country Status (2)

Country Link
CN (2) CN111039947A (zh)
WO (1) WO2020078360A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116003469B (zh) * 2022-03-23 2023-10-17 南京知和医药科技有限公司 嘧啶基抗病毒化合物的制备与使用方法
CN117343064B (zh) * 2022-07-05 2024-04-16 南京知和医药科技有限公司 一种具有抗病毒作用的嘧啶衍生物的制备与应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102224153A (zh) * 2008-09-22 2011-10-19 阵列生物制药公司 作为trk激酶抑制剂的取代的咪唑并[1,2-b]哒嗪化合物
CN102264736A (zh) * 2008-10-22 2011-11-30 阵列生物制药公司 作为TRK激酶抑制剂的取代的吡唑并[1，5-a]嘧啶化合物
WO2019174598A1 (en) * 2018-03-14 2019-09-19 Fochon Pharmaceuticals, Ltd. SUBSTITUTED (2-AZABICYCLO [3.1.0] HEXAN-2-YL) PYRAZOLO [1, 5-a] PYRIMIDINE AND IMIDAZO [1, 2-b] PYRIDAZINE COMPOUNDS AS TRK KINASES INHIBITORS

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102224153A (zh) * 2008-09-22 2011-10-19 阵列生物制药公司 作为trk激酶抑制剂的取代的咪唑并[1,2-b]哒嗪化合物
CN102264736A (zh) * 2008-10-22 2011-11-30 阵列生物制药公司 作为TRK激酶抑制剂的取代的吡唑并[1，5-a]嘧啶化合物
WO2019174598A1 (en) * 2018-03-14 2019-09-19 Fochon Pharmaceuticals, Ltd. SUBSTITUTED (2-AZABICYCLO [3.1.0] HEXAN-2-YL) PYRAZOLO [1, 5-a] PYRIMIDINE AND IMIDAZO [1, 2-b] PYRIDAZINE COMPOUNDS AS TRK KINASES INHIBITORS

Also Published As

Publication number Publication date
CN111039947A (zh) 2020-04-21
WO2020078360A1 (zh) 2020-04-23

Similar Documents

Publication Publication Date Title
CN111153901B (zh) 一类含氮稠杂环类shp2抑制剂化合物、制备方法和用途
EP3712151B1 (en) (s)-1'-(8-((2-amino-3-chloropyridin-4-yl)thio)imidazo[1,2-c]pyrimidin-5-yl)-5,7-dihydrospiro[cyclopenta[b]pyridine-6,4'-piperidine]-5-amine as shp2 inhibitor for the treatment of cancer
WO2021018287A1 (zh) 一种螺芳环化合物、其制备及应用
WO2019158019A1 (zh) 嘧啶并环化合物及其制备方法和应用
KR101469334B1 (ko) Ｎ-9-치환된 퓨린 화합물, 조성물 및 사용 방법
CN106187915A (zh) 具有alk与egfr双重活性的抑制剂及其制备方法和应用
CN114981268A (zh) 嘧啶-4(3h)-酮类杂环化合物、其制备方法及其在医药学上的应用
TWI822868B (zh) Ｆｇｆｒ４抑制劑、包含其的藥物組合物及其用途
WO2020156437A1 (zh) Akt抑制剂
CN111518100A (zh) 环丙烯并苯并呋喃取代的氮杂芳基化合物及其应用
CN115477640A (zh) 作为parp7抑制剂的哒嗪酮类化合物
CN113242858A (zh) 一类蛋白受体激酶抑制剂的制备和应用
AU2010229140A1 (en) Novel aminopyridine derivatives having Aurora A selective inhibitory action
CN112300173B (zh) 一类含氮多环类化合物、制备方法和用途
CN111747954B (zh) 吡嗪化合物和其用途
CN114641476B (zh) 一类蛋白受体激酶抑制剂的制备和应用
WO2023143147A1 (zh) 一种哒嗪并吡啶酮类化合物、其药物组合物及应用
CN112279837A (zh) 吡嗪化合物和其用途
WO2019057112A1 (zh) 2-取代吡唑氨基-4-取代氨基-5-嘧啶甲酰胺类化合物、组合物及其应用
TWI847445B (zh) 一種噠嗪類化合物、其藥物組合物及應用
CN111763217B (zh) 一类噻吩并氮杂环类化合物、制备方法和用途
WO2023046030A1 (zh) 一种egfr小分子抑制剂、含其的药物组合物及其用途
WO2023116763A1 (zh) 一种哒嗪类化合物、其药物组合物及应用
WO2024088296A1 (zh) 哌啶并嘧啶类衍生物、其制备方法及其在医药上的应用
EA045554B1 (ru) Ингибитор fgfr4 и его применение

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210810

WD01 Invention patent application deemed withdrawn after publication